MYC and plasma cell myeloma: In MyLa cells, representing tumor cells of mycosis fungoides, silencing of cMyc resulted in resistance to bortezomib, analogously to what has been shown in multiple myeloma, melanoma, breast and cervical carcinomas [12]–[14] (Figure 1A, B).